- Live market news
- Stocks
- VNDA
Vanda Pharmaceuticals Inc
VNDAStockUSA
4.235USD+0.145 (+3.55%)Live · 20 Oct, 16:00 UTC
Key figures
- Previous close
- 4.09
- Open
- 4.10
- Day range
- 4.10 – 4.315
- 52-week range
- —
- Volume
- 43.1K
Latest news on VNDAranked by Oyticker for market impact
- 15Impact
VNDA to present at 2026 EADV dermatology conference
Vanda Pharmaceuticals announced a presentation slot at the 2026 European Academy of Dermatology and Venereology annual meeting, a routine conference participation.
VNDAPharmaceuticalsDermatology - 72Impact
VNDA reports positive Phase III HETLIOZ® results in delayed sleep-wake disorder
Vanda Pharmaceuticals announced positive topline Phase III results for HETLIOZ® (tasimelteon) 20 mg in delayed sleep-wake phase disorder, a pivotal efficacy readout for an approved drug seeking expanded indication.
VNDAPharmaceuticalsSpecialty Pharma
In detailthe same figures as in Oyticker Charts
Performance
1D+3.5%
Ranges & volume
Day4.10 – 4.315
52 weeks—
- Open
- 4.10
- Prev. close
- 4.09
Volume 43.1Kavg —
Risk · 1 year
Not enough historyRisk needs at least a month of daily sessions.
Seasonality
Not enough historySeasonality needs several months of data.
SEC filings
All its filingsWhat VNDA filed
- 29 Oct 2026
- 28 Oct 2026
- 6 Aug 2026
- 5 Aug 2026
- 5 Jun 2026
From SEC EDGAR, the public record of what US-listed companies file. Each document opens on sec.gov.
Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.